Evidence map›Paper›PMID 29162153›Full record

ArticleJournal for immunotherapy of cancer2017

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

I Puzanov, A Diab, K Abdallah, C O Bingham, C Brogdon, R Dadu, L Hamad, S Kim, M E Lacouture, N R LeBoeuf and 12 more

Registry-linked trialOpen access · goldAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07174453 (A Late Phase Randomized Open-Label Multi Cohort Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies), which is not on this map. Cited by 1,096 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,096citing papers in PubMed, 17 pooled it
81.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07174453 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

A Late Phase Randomized Open-Label Multi Cohort Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

TypeinterventionalSponsorUniversity of Kansas Medical CenterRan2025 to 2029Enrolled192ConditionsSolid Tumor MalignanciesArmsNivolumab, Pembrolizumab
3 · Its place in the literature

Who cites it

1,096 citing papers in PubMed, 17 syntheses or guidelines pooled it, 1,943 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Progress in immunotherapy for resectable head and neck squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2025
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Article
  19. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
  20. Article

1,036 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 2 countries.

I PuzanovRoswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA.
A DiabUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
K AbdallahMerck & Co., Inc., Upper Gwynedd, PA, USA.
C O BinghamJohns Hopkins University, Baltimore, MD, USA.
C BrogdonBristol-Myers Squibb Company, New York, NY, USA.
R DaduUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
L HamadRoswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA.
S KimUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
M E LacoutureMemorial Sloan Kettering Cancer Center, New York, NY, USA.
N R LeBoeufDana Farber/Brigham and Women's Cancer Center, Boston, MA, USA.
D LenihanWashington University in St Louis, St Louis, MO, USA.
C OnofreiIndiana University, Indianapolis, IN, USA.
V ShannonUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
R SharmaRoswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA.
A W SilkMassachusetts General Hospital, Boston, MA, USA.
D SkondraUniversity of Chicago, Chicago, IL, USA.
M E Suarez-AlmazorUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y WangUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
K WileyOncology Nursing Society, Pittsburgh, PA, USA.
H L KaufmanMassachusetts General Hospital, Boston, MA, USA.
M S ErnstoffRoswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA. Marc.Ernstoff@RoswellPark.org.
Society for Immunotherapy of Cancer Toxicity Management Working Group
Roswell Park Comprehensive Cancer Center · USThe University of Texas MD Anderson Cancer Center · USJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · USOncology Nursing Society · USWashington University in St. Louis · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USUniversity of Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs' therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained acute or chronic immune response. Skin, gut, endocrine, lung and musculoskeletal irAEs are relatively common, whereas cardiovascular, hematologic, renal, neurologic and ophthalmologic irAEs occur much less frequently. The majority of irAEs are mild to moderate in severity; however, serious and occasionally life-threatening irAEs are reported in the literature, and treatment-related deaths occur in up to 2% of patients, varying by ICI. Immunotherapy-related irAEs typically have a delayed onset and prolonged duration compared to adverse events from chemotherapy, and effective management depends on early recognition and prompt intervention with immune suppression and/or immunomodulatory strategies. There is an urgent need for multidisciplinary guidance reflecting broad-based perspectives on how to recognize, report and manage organ-specific toxicities until evidence-based data are available to inform clinical decision-making. The Society for Immunotherapy of Cancer (SITC) established a multidisciplinary Toxicity Management Working Group, which met for a full-day workshop to develop recommendations to standardize management of irAEs. Here we present their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy.

Indexed as

Clinical Decision-MakingEvidence-Based MedicineHumansImmunotherapyNeoplasmsNeurotoxicity SyndromesPractice Guidelines as TopicSocieties, MedicalImmune checkpoint inhibitorImmune-related adverse eventsToxicity

Identifiers

PMID29162153
PMCPMC5697162
OpenAlexW2768429453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.